As FDA Filing Approaches for Tab-Cel in EBV+ PTLD, Decades of Science Bear Fruit
Approved in Europe, tabelecleucel may soon be considered by FDA to treat patients who develop Epstein-Barr virus following a transplant, which then triggers a type of deadly lymphoma that may not respond to traditional therapy. Tab-cel, an allogeneic T-cell therapy, comes 30 years after the discovery that T cells might offer hope, followed by decades of research on how to harness them without the side effects.
United States Dana Farber Cancer Institute United Kingdom Rajani Dinavahi Susan Prockop Biotherapeutic Ebvallo Tabelecleucel
Source: ajmc.com